Drug Repurposing Market Research Report Information By Types (Disease-centric, Target-centric And Drug-centric), By Therapeutic Area (Same Therapeutic Area And Different Therapeutic Area), By Drug Molecules (Biologics, Small Molecule), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL DRUG REPURPOSING MARKET, BY TYPES

6.1. Overview

6.2. Disease-centric

6.3. Target-centric

6.4. Drug-centric

7. GLOBAL DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA

7.1. Overview

7.2. Same Therapeutic Area

7.3. Different Therapeutic Area

8. GLOBAL DRUG REPURPOSING MARKET, BY DRUG MOLECULES

8.1. Overview

8.2. Biologics

8.3. Small Molecule

9. GLOBAL DRUG REPURPOSING MARKET, BY REGION

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. COMPETITIVE LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Drug Repurposing Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Drug Repurposing Market

10.7. Key Developments and Growth Strategies

10.7.1. New Product Launch/Service Deployment

10.7.2. Merger & Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income, 2023

10.8.2. Major Players R&D Expenditure. 2023

11. COMPANY PROFILES

11.1. Algernon Pharmaceuticals

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Biovista

11.2.1. Company Overview

11.2.2. Financial Overview

11.2.3. Products Offered

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Celentyx Ltd

11.3.1. Company Overview

11.3.2. Financial Overview

11.3.3. Products Offered

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. CHEMBIO DISCOVERY, INC.

11.4.1. Company Overview

11.4.2. Financial Overview

11.4.3. Products Offered

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. CHORD THERAPEUTICS SA

11.5.1. Company Overview

11.5.2. Financial Overview

11.5.3. Products Offered

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. EXCELRA

11.6.1. Company Overview

11.6.2. Financial Overview

11.6.3. Products Offered

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Fios Genomics

11.7.1. Company Overview

11.7.2. Financial Overview

11.7.3. Products Offered

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. LANTERN PHARMA, INC.

11.8.1. Company Overview

11.8.2. Financial Overview

11.8.3. Products Offered

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. NOVARTIS AG

11.9.1. Company Overview

11.9.2. Financial Overview

11.9.3. Products Offered

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Paradigm Biopharmaceuticals Ltd

11.10.1. Company Overview

11.10.2. Financial Overview

11.10.3. Products Offered

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Predictive Oncology

11.11.1. Company Overview

11.11.2. Financial Overview

11.11.3. Products Offered

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Segue Therapeutics, LLC

11.12.1. Company Overview

11.12.2. Financial Overview

11.12.3. Products Offered

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. Sosei Group Corporation

11.13.1. Company Overview

11.13.2. Financial Overview

11.13.3. Products Offered

11.13.4. Key Developments

11.13.5. SWOT Analysis

11.13.6. Key Strategies

11.14. Teva Pharmaceutical Industries

11.14.1. Company Overview

11.14.2. Financial Overview

11.14.3. Products Offered

11.14.4. Key Developments

11.14.5. SWOT Analysis

11.14.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL DRUG REPURPOSING MARKET, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL DRUG REPURPOSING MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 4 GLOBAL DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 5 GLOBAL DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 7 NORTH AMERICA: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 8 NORTH AMERICA: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 9 US: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 10 US: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 11 US: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 12 CANADA: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 13 CANADA: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 14 CANADA: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 1 EUROPE: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 2 EUROPE: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 3 EUROPE: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 4 GERMANY: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 5 GERMANY: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 6 GERMANY: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 7 FRANCE: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 8 FRANCE: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 9 FRANCE: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 10 ITALY: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 11 ITALY: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 12 ITALY: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 13 SPAIN: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 14 SPAIN: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 15 SPAIN: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 16 UK: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 17 UK: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 18 UK: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 19 REST OF EUROPE: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 20 REST OF EUROPE: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 21 REST OF EUROPE: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 22 ASIA-PACIFIC: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 23 ASIA-PACIFIC: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 24 ASIA-PACIFIC: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 25 JAPAN: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 26 JAPAN: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 27 JAPAN: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 28 CHINA: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 29 CHINA: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 30 CHINA: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 31 INDIA: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 32 INDIA: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 33 INDIA: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 34 AUSTRALIA: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 35 AUSTRALIA: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 36 AUSTRALIA: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 37 SOUTH KOREA: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 38 SOUTH KOREA: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 39 SOUTH KOREA: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 40 REST OF ASIA-PACIFIC: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 41 REST OF ASIA-PACIFIC: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 42 REST OF ASIA-PACIFIC: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 43 REST OF THE WORLD: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 44 REST OF THE WORLD: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 45 REST OF THE WORLD: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 46 MIDDLE EAST: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 47 MIDDLE EAST: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 48 MIDDLE EAST: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 49 AFRICA: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 50 AFRICA: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 51 AFRICA: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

TABLE 52 LATIN AMERICA: DRUG REPURPOSING MARKET, BY TYPES , 2019-2032 (USD BILLION)

TABLE 53 LATIN AMERICA: DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)

TABLE 54 LATIN AMERICA: DRUG REPURPOSING MARKET, BY DRUG MOLECULES, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL DRUG REPURPOSING MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL DRUG REPURPOSING MARKET

FIGURE 4 GLOBAL DRUG REPURPOSING MARKET, SHARE (%), BY TYPES , 2023

FIGURE 5 GLOBAL DRUG REPURPOSING MARKET, SHARE (%), BY THERAPEUTIC AREA, 2023

FIGURE 6 GLOBAL DRUG REPURPOSING MARKET, SHARE (%), BY DRUG MOLECULES, 2023

FIGURE 7 GLOBAL DRUG REPURPOSING MARKET, SHARE (%), BY REGION, 2023

FIGURE 8 NORTH AMERICA: DRUG REPURPOSING MARKET, SHARE (%), BY REGION, 2023

FIGURE 9 EUROPE: DRUG REPURPOSING MARKET, SHARE (%), BY REGION, 2023

FIGURE 10 ASIA-PACIFIC: DRUG REPURPOSING MARKET, SHARE (%), BY REGION, 2023

FIGURE 11 REST OF THE WORLD: DRUG REPURPOSING MARKET, SHARE (%), BY REGION, 2023

FIGURE 12 GLOBAL DRUG REPURPOSING MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 13 ALGERNON PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 14 ALGERNON PHARMACEUTICALS: SWOT ANALYSIS

FIGURE 15 BIOVISTA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 16 BIOVISTA: SWOT ANALYSIS

FIGURE 17 CELENTYX LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 18 CELENTYX LTD: SWOT ANALYSIS

FIGURE 19 CHEMBIO DISCOVERY, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 20 CHEMBIO DISCOVERY, INC.: SWOT ANALYSIS

FIGURE 21 CHORD THERAPEUTICS SA.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 22 CHORD THERAPEUTICS SA.: SWOT ANALYSIS

FIGURE 23 EXCELRA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 EXCELRA: SWOT ANALYSIS

FIGURE 25 FIOS GENOMICS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 FIOS GENOMICS: SWOT ANALYSIS

FIGURE 27 LANTERN PHARMA, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 LANTERN PHARMA, INC.: SWOT ANALYSIS

FIGURE 29 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 NOVARTIS AG: SWOT ANALYSIS

FIGURE 31 PARADIGM BIOPHARMACEUTICALS LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 PARADIGM BIOPHARMACEUTICALS LTD: SWOT ANALYSIS

FIGURE 33 PREDICTIVE ONCOLOGY: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 PREDICTIVE ONCOLOGY: SWOT ANALYSIS

FIGURE 35 SEGUE THERAPEUTICS, LLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 36 SEGUE THERAPEUTICS, LLC: SWOT ANALYSIS

FIGURE 37 SOSEI GROUP CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 38 SOSEI GROUP CORPORATION: SWOT ANALYSIS

FIGURE 39 TEVA PHARMACEUTICAL INDUSTRIES: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES: SWOT ANALYSIS